KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.

Arrigo F G Cicero, Federica Fogacci, Ivan Cincione

Expert Opin Drug Metab Toxicol 17(9) 1031-1038

PMID34197267
PMCID-
DOI10.1080/17425255.2021.1951222
发表日期2021-07-01
摘要

摘要

Introduction: Bempedoic acid is a first-in-class low-density lipoprotein cholesterol (LDL-C) lowering agent which offers an important opportunity for further LDL-C lowering in statin-intolerant patients or in patients requiring further LDL-C reduction despite maximally tolerated statin therapy.Areas covered: In this review, we examined the pharmacodynamics, pharmacokinetics, clinical efficacy, and safety of bempedoic acid, based on randomized clinical phase III clinical studies and their meta-analyses.Expert opinion: Unlike statins, bempedoic acid is administered as a prodrug and is converted to active form by a liver-specific enzyme. For the liver-specific mechanism of action, bempedoic acid has the potential to reduce the risk of muscle-related adverse events which can limit the utilization and effectiveness of statin therapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。